Next Article in Journal
Ataxia–Telangiectasia Gene (ATM) Mutation Heterozygosity in Breast Cancer: A Narrative Review
Previous Article in Journal
Pharmacologic Interventions for Fatigue in Cancer and Transplantation: A Meta-Analysis
 
 
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
Review

Aromatase Inhibitors in Premenopausal Women with Breast Cancer: The State of the Art and Future Prospects

Clinica di Oncologia Medica e Centro Regionale di Genetica Oncologica, Università Politecnica delle Marche, Ancona, Italy
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2018, 25(2), 168-175; https://doi.org/10.3747/co.25.3735
Received: 4 January 2018 / Revised: 6 February 2018 / Accepted: 5 March 2018 / Published: 1 April 2018
Approximately 11% of patients with breast cancer (BCA) are diagnosed before menopause, and because in most of those patients the tumour expresses a hormone receptor, treatment with endocrine interventions can be applied in any setting of disease (early or advanced). In the past, hormonal treatment consisted only of the estrogen receptor modulator tamoxifen, associated with luteinizing hormone–releasing hormone (LHRH); more recently, aromatase inhibitors (AIS) have come into widespread use. The AIS interfere with the last enzymatic step of estrogen synthesis in which androgens are converted into estrogens. Initially, the AIS were used alone in postmenopausal patients to prevent disease recurrence, but together with LHRH analogs, they can be used in premenopausal patients to produce better estrogen suppression than can be achieved with tamoxifen plus a LHRH analog. Using a systematic review of the scientific literature (prospective and retrospective studies), we set out to assess the efficacy of AIS compared with other endocrine therapy in various disease settings (neoadjuvant, adjuvant, metastatic).
Keywords: breast cancer; aromatase inhibitors; premenopausal women; tamoxifen; lhrh analog; letrozole; anastrozole; exemestane breast cancer; aromatase inhibitors; premenopausal women; tamoxifen; lhrh analog; letrozole; anastrozole; exemestane
MDPI and ACS Style

Pistelli, M.; Della Mora, A.; Ballatore, Z.; Berardi, R. Aromatase Inhibitors in Premenopausal Women with Breast Cancer: The State of the Art and Future Prospects. Curr. Oncol. 2018, 25, 168-175. https://doi.org/10.3747/co.25.3735

AMA Style

Pistelli M, Della Mora A, Ballatore Z, Berardi R. Aromatase Inhibitors in Premenopausal Women with Breast Cancer: The State of the Art and Future Prospects. Current Oncology. 2018; 25(2):168-175. https://doi.org/10.3747/co.25.3735

Chicago/Turabian Style

Pistelli, M., A. Della Mora, Z. Ballatore, and R. Berardi. 2018. "Aromatase Inhibitors in Premenopausal Women with Breast Cancer: The State of the Art and Future Prospects" Current Oncology 25, no. 2: 168-175. https://doi.org/10.3747/co.25.3735

Find Other Styles

Article Access Map by Country/Region

1
Back to TopTop